Suraxavir Marboxil
Phase 3Small molecule
Suraxavir Marboxil is one of 84 small molecule programs targeting Efficacy. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
145 competitors in Efficacy
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Biaxin
AbbViePhase 3
Tivicay
GSKPhase 3
Rogaine
PfizerPhase 3
Rayos
RRoxane Laboratories
Phase 3
Paraplatin
AAvyxa
Phase 3
Alimta
SShawn Eagle
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Insulin 320
Novo NordiskPhase 3
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy1 trial
Influenza1 trial
Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting
Recruiting·—·Phase 3·NCT07236814·384 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Suraxavir Marboxil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details